Educational resource · Last updated September 25, 2026

Mounjaro® Dose Guide

An independent, label-anchored hub for Mounjaro (tirzepatide) dosing logistics—titration, missed doses, presentations, and storage. Not medical advice.

Independence: Not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. Mounjaro®, Zepbound®, and KwikPen® are trademarks of Eli Lilly and Company (or its affiliates).
Titration schedule Missed dose rules
Medical disclaimer: Educational only—not diagnosis, prescription, or personalized dosing advice. Talk to a licensed clinician. Follow the current FDA / DailyMed Prescribing Information and Instructions for Use for your presentation. Label citations checked as of September 25, 2026—verify the live label.
Boxed warning (label theme): FDA-approved tirzepatide products carry a boxed warning regarding thyroid C-cell tumors observed in rodents. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. People with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should review contraindications with a clinician and the official label. See also our sister hub on tirzepatide side effects.

What this hub covers

Label-based dosing logistics

We paraphrase publicly available US label themes for starting dose, weekly schedule, titration steps, missed-dose windows, storage, and presentation differences—so you can ask better questions of your clinician.

Indication clarity

In the US, Mounjaro® is the Lilly brand of tirzepatide indicated for type 2 diabetes (see current label for full indication language, including any cardiovascular risk-reduction framing). Zepbound® is a separate Lilly brand for weight management / OSA populations. Same molecule—different brands and labeled uses. Do not DIY-switch brands.

Compounded ≠ Mounjaro®: Compounded tirzepatide preparations are not FDA-approved and are not Mounjaro® or Zepbound®. Never call compounded products “generic Mounjaro.” For a deeper comparison, see compounded vs Zepbound® on Tirzepatide Hub.

Dose topic guides

Titration schedule

2.5 mg steps after ≥4 weeks—what the US label says.

 Missed dose

96-hour and 72-hour spacing themes from the label.

 Vial vs pen / KwikPen®

Presentations compared; never share pens.

 Storage & handling

Fridge, room temperature, discard windows.

 Mounjaro® vs Zepbound® dosing

Same molecule, different US indications.

 Access / telehealth

After you understand dosing—how pathways work.

Science sister site

For dual GIP/GLP-1 mechanism, SURMOUNT evidence, cost deep-dives, and side-effect detail, visit our sister educational hub:

FAQ

What is the usual Mounjaro starting dose per the US label?

Per the US Prescribing Information, treatment typically starts at 2.5 mg once weekly. The 2.5 mg dose is for initiation and is not intended for glycemic control. Confirm with your clinician and the current label.

How often is Mounjaro injected?

Once weekly, as described in the US label and the Instructions for Use for your presentation.

Is this site affiliated with Eli Lilly?

No. We are an independent educational publisher. Not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.

Should I follow a website or my clinician for my dose?

Always follow your licensed clinician and the official Prescribing Information / IFU. This site does not personalize doses.